ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8B | $3.7B | $2.2B | $1.8B | $1.0B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $101M | $96M |
| Cost of revenue | $971M | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $1.8M | $0 | — | — | — | — |
| Gross profit | $3.8B | $3.0B | $1.9B | $1.6B | $897M | $729M | $419M | $195M | $73M | $90M | — | — | — | — |
| R&D | $1.5B | $1.3B | $1.1B | $1.0B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $106M | $109M | $97M |
| SG&A | $1.3B | $1.2B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | — | — | — |
| Other operating expenses | $6.7M | $4.7M | $17M | $42M | $29M | $25M | $3.9M | — | — | — | — | — | — | — |
| Operating income | $1,000M | $502M | −$177M | −$282M | −$785M | −$709M | −$828M | −$939M | −$815M | −$500M | −$425M | −$44M | −$48M | −$28M |
| Non-operating income | −$275M | −$178M | −$200M | −$151M | −$342M | −$143M | −$27M | $54M | $54M | $9.2M | $14M | $1.1M | $1.1M | $2.3M |
| Pretax income | $725M | $323M | −$377M | −$434M | −$1.1B | −$852M | −$856M | −$885M | −$761M | −$491M | −$410M | −$43M | −$47M | −$26M |
| Taxes | −$8.4M | $9.4M | −$99M | $6.7M | $4.2M | $680K | $2.7M | $863K | $823K | $0 | $0 | $514K | $582K | $719K |
| Net income | $733M | $314M | −$278M | −$440M | −$1.1B | −$853M | −$858M | −$886M | −$761M | −$491M | −$410M | −$44M | −$48M | −$26M |
| Diluted EPS | $5.74 | $2.33 | −$2.18 | −$3.52 | −$9.30 | −$7.20 | −$7.46 | −$8.11 | −$7.57 | −$5.42 | −$4.79 | −$1.04 | −$1.14 | — |
| Diluted shares | — | 134.7M | 127.7M | 124.9M | 121.7M | 118.5M | 115.0M | 109.3M | 100.6M | 90.6M | 85.6M | 42.0M | — | — |
| Revenue growth | — | +65.2% | +23.0% | +76.2% | +22.9% | +71.3% | +124.3% | +193.4% | −16.7% | +90.7% | — | −0.5% | +4.5% | — |
| Gross margin | 79.8% | 81.8% | 86.4% | 85.3% | 86.5% | 86.4% | 84.9% | 88.6% | 97.6% | 100.0% | — | — | — | — |
| Operating margin | 20.8% | 13.5% | −7.9% | −15.4% | −75.7% | −83.9% | −168.1% | −427.5% | −1,087.6% | −556.2% | −900.3% | −44.1% | −47.9% | −28.9% |
| Net margin | 15.3% | 8.4% | −12.4% | −24.1% | −109.0% | −101.0% | −174.1% | −403.2% | −1,016.6% | −545.9% | −869.6% | −43.5% | −47.3% | −27.3% |